Abstract: Provided are ibrutinib polymorphs, e.g., crystalline ibrutinib Forms III, IV, V, VI, VII, VIII and Form IX and processes for producing these crystalline forms, stable amorphous ibrutinib and processes for preparing stable amorphous ibrutinib, pharmaceutical compositions comprising these forms and methods of using these crystalline and amorphous forms.
Type:
Grant
Filed:
March 23, 2015
Date of Patent:
February 6, 2018
Assignee:
PERRIGO API LTD.
Inventors:
Itai Adin, Sonia Krivonos, Yevgeny Rozenblat, Alex Weisman, Ana Fernadez Casares, Gloria Ten Figas, Revital Ben-Daniel
Abstract: The present invention provides crystalline forms of efinaconazole, including crystalline efinaconazole forms designated herein as Form A, Form B and Form C, crystalline efinaconazole p-toluenesulfonate salt designated herein as Form I, and processes for their preparation.
Type:
Application
Filed:
December 2, 2015
Publication date:
January 4, 2018
Applicant:
Perrigo API Ltd.
Inventors:
Itai ADIN, Hila ELAZARI-SHALOM, Ori RORILK, Yana SERY
Abstract: Provided are ibrutinib polymorphs, e.g., crystalline ibrutinib Forms III, IV, V, VI, VII, VIII and Form IX and processes for producing these crystalline forms, stable amorphous ibrutinib and processes for preparing stable amorphous ibrutinib, pharmaceutical compositions comprising these forms and methods of using these crystalline and amorphous forms.
Type:
Application
Filed:
March 23, 2015
Publication date:
August 10, 2017
Applicant:
PERRIGO API LTD.
Inventors:
Itai ADIN, Sonia KERIVONOS, Yevgeny ROZENBLAT, Alex WEISMAN, Ana FERNADEZ CASARES, Gloria TEN FIGAS, Revital BEN-DANIEL